Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Research Abstract |
We carried out a clinical study to evaluate a novel automated assay system for cytokeratin 19 (CK19) mRNA, the one-step nucleic acid amplification (OSNA) method, to detect the lymph node metastasis of OSCC. The accuracy of OSNA assay was nearly 95%, but it could not detect occult metastasis in case of no or low expression of CK19 mRNA in the primary tumor. We identified ANXA8L2 that were commonly expressed in all OSCC metastatic lymph nodes but not in benign lymph nodes. This molecular marker and CK19 detected all histopathological metastasis-positive lymph nodes in OSCC. We confirmed the expression of ANXA8L2 mRNA in all OSCC primary tumor tissues. ANXA8L2 and CK19 could be useful molecular markers for detecting lymph node metastasis of OSCC.
|